The Struggle of British Science: Nowhere to Turn.
The lack of an overarching strategy for the UK's life sciences sector is throttling the growth of some of the country's most promising companies, according to Reuters interviews with 17 people with knowledge of the challenges. The dearth of state-of-the-art labs in cities such as Oxford and Cambridge is just one example of the problem. The industry figures, from biotech bosses, property developers, industry sources to investors, all spoke of a growing frustration with the lack of a coherent approach in Britain to everything from lab space to funding, talent, suppliers, affordable homes, transport, water and power.